Role of Postoperative Radiotherapy on High-Risk Stage pII-IA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study

被引:2
|
作者
Chen, Zu Yi [1 ]
Liang, Huan Wei [2 ]
Liu, Yang [2 ]
Huang, Wei [2 ]
Pan, Xin Bin [2 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Canc Hosp, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Med Univ, Canc Hosp, Dept Radiat Oncol, Nanning 530021, Guangxi, Peoples R China
基金
英国科研创新办公室;
关键词
Non-small cell lung cancer; Stage pIIIA-N2; Lymph node ratio; Postoperative radiotherapy; VINORELBINE PLUS CISPLATIN; LYMPH-NODE RATIO; PHASE-III; SURVIVAL; RADIATION; CONCURRENT; MANAGEMENT; THERAPY; SURGERY; MODELS;
D O I
10.14740/wjon1832
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of the study was to assess the effectiveness of postoperative radiotherapy in high -risk patients with stage pIIIA-N2 non -small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy. Methods: Data from NSCLC patients within the Surveillance, Epidemiology, and End Results (SEER) database were analyzed. The study examined the association between lymph node ratio (LNR) and both cancer -specific survival (CSS) and overall survival (OS) using restricted cubic spline curves. Patients were categorized into highand low -risk groups based on established LNR cut-off values, and survival outcomes were compared between those receiving postoperative radiotherapy and those who did not within the high -risk group. Results: The study included 1,690 patients. An LNR threshold of 0.29 was identified for both CSS and OS. Patients with an LNR > 0.29 demonstrated significantly worse CSS (hazard ratio (HR) = 1.56, 95% confidence interval (CI): 1.37 - 1.78; P < 0.001) and OS (HR = 1.44, 95% CI: 1.28 - 1.62; P < 0.001) compared to those with an LNR < 0.29. In the high -risk group (LNR >= 0.29), postoperative radiotherapy did not significantly affect CSS (HR = 0.98, 95% CI: 0.82 - 1.17; P = 0.809) or OS (HR = 0.95, 95% CI: 0.81 - 1.11; P = 0.533). Conclusions: LNR is a significant prognostic factor in patients with stage pIIIA-N2 NSCLC post complete resection and adjuvant chemotherapy. A higher LNR (> 0.29) is associated with poorer CSS and OS. However, postoperative radiotherapy does not confer survival benefits in these high -risk patients. Our findings suggest that postoperative radiotherapy should not be routinely performed in this subgroup. Further research is required to explore effective treatment strategies for these patients.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [41] Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives
    Wang, Pascal
    Duchemann, Boris
    Chouahnia, Kader
    Matton, Lise
    Benabadji, Ambre
    Zelek, Laurent
    Popotte, Hosni
    Paix, Adrien
    BULLETIN DU CANCER, 2023, 110 (01) : 101 - 112
  • [42] Effect of Age on Adjuvant Chemotherapy after Resection of Non-Small Cell Lung Cancer
    Zhai, Xiaoyu
    Wang, Ziping
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S677 - S678
  • [43] Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer
    Zhai, Xiaoyu
    Yang, Lu
    Chen, Sipeng
    Zheng, Qiwen
    Wang, Ziping
    CANCER MEDICINE, 2016, 5 (09): : 2286 - 2293
  • [44] Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer
    Kefeli, Umut
    Kaymaz, Samet
    Aydin, Dincer
    Isik, Deniz
    Cabuk, Devrim
    Sonkaya, Alper
    Acikgoz, Ozgur
    Isik, Ulas
    Ozden, Ercan
    Uygun, Kazim
    BEZMIALEM SCIENCE, 2019, 7 (04): : 265 - 270
  • [45] Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer
    Ou, Wei
    Sun, Hai-bo
    Ye, Xiong
    Zhang, Bin-bin
    Yang, Hua
    Fang, Qin
    Li, Pan
    Wang, Si-yu
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1033 - 1041
  • [46] Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
    Ding, Xiao
    Dai, Honghai
    Hui, Zhouguang
    Ji, Wei
    Liang, Jun
    Lv, Jima
    Zhou, Zongmei
    Yin, Weibo
    He, Jie
    Wang, Luhua
    RADIATION ONCOLOGY, 2012, 7
  • [47] A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer
    Takamori, S
    Rikimaru, T
    Hayashi, A
    Tayama, K
    Mitsuoka, M
    Fujimoto, K
    Horiuchi, M
    Hayabuchi, N
    Oizumi, K
    Shirouzu, K
    LUNG CANCER, 2000, 29 (01) : 49 - 56
  • [48] Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection
    Kim, Mi Young
    Wu, Hong-Gyun
    Kim, Hak Jae
    Heo, Dae-Seog
    Kim, Young Whan
    Kim, Dong-Wan
    Lee, Se-Hoon
    Kim, Joo Hyun
    Kim, Young Tae
    Kang, Chang-Hyun
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (01): : 44 - 52
  • [49] A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
    Song, Xue
    Xie, Yangyang
    Deng, Haoran
    Yu, Fei
    Wang, Shiqiang
    Lou, Yafang
    CANCER CONTROL, 2023, 30
  • [50] Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection
    Chen, Shiqi
    Yang, Siqian
    Zhao, Yue
    Zhang, Yang
    Huang, Qingyuan
    Wu, Haoxuan
    Hu, Hong
    Sun, Yihua
    Zhang, Yawei
    Xiang, Jiaqing
    Ye, Ting
    Chen, Haiquan
    THORACIC CANCER, 2024, 15 (03) : 258 - 265